Cronos Group Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. Amounts below are U.S. dollars unless otherwise stated. This is an annual report, not a standalone fourth-quarter earnings release.
Business context
Cronos is a cannabinoid company selling cannabis products under Spinach, PEACE NATURALS and Lord Jones. Following its second-quarter 2023 exit from U.S. hemp-derived cannabinoid products, it reported one segment covering Canada and Israel; the exited U.S. business is classified as discontinued operations. The company also began distributing products in Germany and Australia through partners.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue before excise taxes | $120.3 million | $109.3 million |
| Excise taxes | $33.0 million | $22.6 million |
| Net revenue | $87.2 million | $86.7 million |
| Gross profit / margin | $11.9 million / 14% | $15.4 million / 18% |
| Operating loss | $84.8 million | $111.4 million |
| Net loss attributable to Cronos Group | $74.0 million | $168.7 million |
| Adjusted EBITDA, non-GAAP | $(63.7) million | $(80.6) million |
| Cash used in operating activities | $42.8 million | $88.9 million |
| Cash and cash equivalents | $669.3 million | $764.6 million |
| Short-term investments | $192.2 million | $113.1 million |
At year-end, total cash and short-term investments were $861.5 million, down $16.2 million from 2022. Management said existing cash and investments should fund operations and capital expenditures for the next 12 months. Cronos reported no external financing or debt; total liabilities were $44.0 million, including $2.6 million of lease obligations. Shareholders’ equity was $1.10 billion. The company also held $74.6 million of loans receivable, largely related to Cronos GrowCo.
Changes, outlook and notable items
- Net revenue was nearly flat as growth in Canadian adult-use sales and new international shipments was largely offset by lower Israeli sales. On a constant-currency basis, net revenue rose 6%; this is a company-reported non-GAAP comparison.
- Gross profit fell 23% and gross margin declined four percentage points. Management cited weaker Israeli flower sales, Canadian flower price/mix and higher excise taxes as a share of revenue, plus an $0.8 million inventory write-down associated with the Winnipeg facility wind-down.
- Operating expenses declined 24%, mainly on lower general and administrative, R&D, restructuring and share-based compensation costs. Higher sales and marketing spending partly offset the reductions.
- Net loss improved, but results included $51.2 million of net interest income, a $23.4 million non-cash impairment of the PharmaCann option, a $12.0 million loss on revaluation of financial instruments, and a $3.4 million impairment of a Ginkgo-related license. The company recorded a $3.2 million income tax benefit, compared with $34.2 million of tax expense in 2022.
- Management provided no quantified revenue, profit or cash-flow guidance. It expects to use available funds for core operations, capital expenditures, product development and strategic partnerships; continued operating losses and negative operating cash flow remain risks.
- Cronos plans to wind down and sell its Winnipeg fermentation facility and announced organization-wide cost reductions. It incurred $0.7 million of Winnipeg wind-down costs and $0.8 million of organization-wide reduction costs in 2023, and expected about $0.1 million of additional costs for each initiative. The Winnipeg facility was not classified as held for sale at year-end.
- A sale-leaseback of the Peace Naturals Campus was agreed for C$23 million cash, subject to closing conditions including Health Canada approval for site-boundary changes. The parties waived the lease condition on February 29, 2024; completion remained conditional. The contemplated lease has a five-year initial term and one five-year renewal option.
- The Israel-Hamas War disrupted imports and adversely affected sales; facilities had not been damaged as of the filing, but war-related losses are not covered by commercial insurance. An Israeli investigation into alleged dumping of Canadian medical cannabis imports could affect imports or impose duties. The filing says the outcome is uncertain.
- Three Canadian cannabis distributors accounted for 66% of 2023 revenue before excise taxes. Altria owned approximately 41.1% of Cronos and held significant governance and ownership-maintenance rights. The company reported no dividends and does not intend to pay them in the foreseeable future.
Risks, contingencies and controls
Key risks include ongoing losses, price competition and possible inventory write-downs, reliance on Canadian provincial purchasers and Cronos GrowCo for supply, evolving cannabis regulation and licensing, foreign-exchange exposure, and the effects of the conflict in Israel. The PharmaCann option is exposed to valuation uncertainty and depends in part on U.S. regulatory developments; its estimated ownership interest was approximately 5.9% on a fully diluted basis at year-end.
Legal matters include a certified Canadian shareholder class action relating to prior financial disclosures, a pending motion for reconsideration in a U.S. shareholder action dismissed with prejudice, and an Israeli consumer class-action claim seeking ILS 420 million against multiple parties, including Cronos Israel entities. The company said it could not predict outcomes and did not expect ordinary-course proceedings, individually or collectively, to materially affect consolidated financial condition, though they could affect results in a particular period.
The SEC settlement imposed restrictions on reliance on certain securities-law safe harbors and private-offering exemptions; the company also settled with the Ontario Securities Commission. Cronos disclosed two restatements and seven material weaknesses in the preceding five years. Management and KPMG reported effective internal control over financial reporting at December 31, 2023, and the previously identified IT access-control weakness was reported remediated. KPMG issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether revenue growth, gross-margin recovery and reduced cash burn continue, particularly in Canada and Israel; review reported GAAP results alongside non-GAAP Adjusted EBITDA.
- Whether the Peace Naturals sale-leaseback closes, Health Canada approvals are obtained, and the Winnipeg facility is sold on acceptable terms.
- Whether Israel-related disruptions, import restrictions or the anti-dumping investigation materially affect supply, demand or costs.
- The carrying value and assumptions underlying the PharmaCann option, including dilution and U.S. regulatory scenarios; also monitor the Vitura investment valuation.
- Customer and supplier concentration, including provincial purchaser exposure and Cronos GrowCo’s role as a principal raw-material source.
- Progress on litigation, regulatory compliance and internal-control remediation, given the restatements and prior control weaknesses.